We compared oral temafloxacin, a new fluoroquinolone agent, with vancomycin, each with and without rifampin, in the therapy of rats with aortic valve endocarditis caused by a clinical isolate of methicillin-resistant Staphylococcus aureus. The temafloxacin, vancomycin, and rifampin MICs and MBCs were 0.78 and 1.56, 1.56 and 3.13, and <0.024 and 0.78 ,ug/ml, respectively. The animals were classified into the following six treatment groups: vancomycin (60 mg/kg) ± rifampin (6 mg/kg) each intramuscularly every 12 h for 5 days; temafloxacin (100 mg/kg) orally ± rifampin (6 mg/kg) intramuscularly every 12 h for 5 days; rifampin (6 mg/kg) intramuscularly every 12 h for 5 days; and untreated controls. All regimens with either vancomycin or temafloxacin resulted in improved survival over controls, but only temafloxacin regimens resulted in a significant reduction in bacterial counts in vegetations. These data support further investigation of the efficacy of temafloxacin in treating serious infections caused by methicillin-resistant S. aureus.
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Staphylococcus aureus is a common cause of infective endocarditis, and cases of endocarditis caused by methicillin-resistant S. aureus (MRSA) are increasing in frequency, especially among intravenous drug users (8) . Treatment of these infections requires prolonged use of intravenous vancomycin alone or in combination with rifampin or gentamicin (11, 12) . This usually necessitates a long hospital stay, and, in intravenous drug users with limited venous access, may require placement of a Hickman catheter or similar device. An effective drug that could be administered orally would be of great benefit to these patients. Temafloxacin is a new fluoroquinolone compound that has good activity against staphylococci including MRSA (5, 9). According to data from the manufacturers (Abbott Laboratories, North Chicago, Ill.), oral administration of the drug in humans results in levels in serum and tissue above the MBCs for these organisms (9) . The purpose of this study was to compare orally administered temafloxacin with parenteral vancomycin, each with and without rifampin, for the treatment of endocarditis caused by MRSA in rats.
MATERIALS AND METHODS
Organism. The strain of MRSA used in this study was isolated from a patient with endocarditis. It was shown to be methicillin resistant by growth on Mueller-Hinton agar containing 20 ,ug of methicillin per ml. Stock cultures were prepared by incubating the organism in Mueller-Hinton broth (MHB) for 18 h at 37°C and freezing 1-ml samples at -70°C. At the time of each experiment, a frozen sample was subcultured into MHB and incubated overnight at 37°C.
In vitro studies. The MICs and MBCs of temafloxacin, vancomycin, and rifampin were determined by standard serial dilution techniques with inocula of 105 CFU/ml (7). The MIC was defined as the lowest concentration of antimicrobial agent that prevented turbidity after 24 h of incubation. The MBC was defined as the lowest concentration that killed 99.9% of the organisms after 24 h, as determined by quantitative culture of each nonturbid MIC dilution.
The survival of 3 x 10' CFU of MRSA per ml was studied * Corresponding author.
in flasks of MHB with the following antimicrobial agents: temafloxacin (3 jig/ml), vancomycin (25 jig/mi), rifampin (1 jig/ml), temafloxacin (3 jig/ml) plus rifampin (1 jig/mI), and vancomycin (25 jig/ml) plus rifampin (1 jig/ml). The antimicrobial concentrations were based on levels achievable in human serum. Kill curves were constructed by quantitative culture of a sample from each flask at 0, 3, 6, and 24 h (2). Additional kill curves were constructed by using starting inocula of 5 x 108 or 106 CFU/ml in flasks containing temafloxacin (6 jig/ml) or vancomycin (25 jig/ml) each in MHB and in rat serum. Plates were incubated at 37°C for 48 h.
Pharmacokinetic studies. At 18 h after infection, rats were given temafloxacin (100 mg/kg) by gastric lavage and were sacrificed at 1, 2, 3, 4, 6, 8, and 10 h following the administration of the dose. Antibiotic concentrations were determined in serum and vegetations by a disk diffusion method with Klebsiella pneumoniae as the test organism (1).
Therapeutic studies. Male Sprague-Dawley rats (Harlan Sprague-Dawley, Altamonte, Vt.) weighing 200 to 300 g were anesthetized. The right carotid artery of each was cannulated, and the catheter was advanced across the aortic valve (10) . After 24 h, each animal was inoculated with 106 CFU of MRSA in 1 ml of MHB via the tail vein. This inoculum produced endocarditis in all rats.
At 18 h after infection, the following treatment regimens were begun: temafloxacin (100 mg/kg) by gavage every 12 h; vancomycin (60 mg/kg) intramuscularly every 12 h; rifampin (6 mg/kg) intramuscularly every 12 h; temafloxacin (100 mg/kg) by gavage plus rifampin (6 mg/kg) intramuscularly every 12 h; vancomycin (60 mg/kg) intramuscularly plus rifampin (6 mg/kg) intramuscularly every 12 h. Each treatment regimen was administered for 5 days, and survivors were sacrificed 12 h after the last dose. Groups of untreated controls were sacrificed at the time of the onset of antimicrobial therapy and 12 h after the last dose of antimicrobial therapy (18 and 150 h after infection). The doses of vancomycin and temafloxacin were those required to result in peak concentrations similar to those achieved in humans (6; unpublished data from Abbott Laboratories).
At the time of sacrifice, all valvular vegetations were Survival of S. aureus in MHB (control) and MHB containing vancomycin (25 ,ug/ml), temafloxacin (3 ,ug/ml), rifampin (1 ,tg/ml), vancomycin (25 ,ug/ml) plus rifampin (1 ,ug/ml), or temafloxacin (3 ,ug/ml) plus rifampin (1 ,ug/ml).
excised, pooled, and weighed. Vegetations from each animal were homogenized in 0. Fig. 1 . Temafloxacin was more rapidly bactericidal than was vancomycin. Addition of rifampin to either temafloxacin or vancomycin decreased the bactericidal rate, thus demonstrating antagonism. The use of rat serum as the growth medium increased the bactericidal rate with vancomycin and to a slight degree with temafloxacin (Fig. 2) .
Pharmacokinetic studies. The pharmacokinetic study results with temafloxacin are shown in of vancomycin in our study are unclear. The levels of vancomycin in serum at both peak and trough were above the MBCs for the organism. Vancomycin is not highly protein bound, and the in vitro studies in serum showed an increased rate of bactericidal activity. Studies from this laboratory demonstrated high levels of vancomycin in homogenized rat vegetations (6) . However, recent studies with radiolabeled teicoplanin, a glycopeptide similar to vancomycin, showed good penetration of teicoplanin superficially into cardiac vegetations but poor and uneven penetration deep into the vegetations (A. C. Cremieux, J. M. Vallois, B. Maziere, M. Ottoviani, A. Bouvet, and C. Carbon, Program Abstr. 27th Intersci. Conf. Antimicrob. Agents Chemother., abstr. no. 922, 1987) . Perhaps the poor results with vancomycin in this study can be explained by similar poor penetration deep into the vegetations or by strain differences in staphylococci.
Vancomycin is successful in the majority of cases of MRSA endocarditis, and wide experience with it dictates its continued use as the drug of choice for such infections (12) . However, vancomycin is inconvenient to administer because it must be given intravenously and some patients need alternate therapy either because of lack of venous access or intolerance of the drug. The findings of this study support further evaluation of temafloxacin for the treatment of staphylococcal infections.
